The MR neuroimaging protocol for the Accelerating Medicines Partnership® Schizophrenia Program

作者：Michael P. Harms, Kang Ik K. Cho, Alan Anticevic, Nicolas R. Bolo, Sylvain Bouix, Dylan Campbell, Tyrone D. Cannon, Guillermo Cecchi, Mathias Goncalves, Anastasia Haidar, Dylan Hughes, Igor Izyurov, Omar John, Tina Kapur, Nicholas Kim, Elana Kotler, Marek R. Kubicki, Joshua M. Kuperman, Kristen Laulette, Ulrich Lindberg, Christopher Johnson Markiewicz, Lipeng Ning, Russell Alan Poldrack, Yogesh Rathi, Paul Romo, Zailyn Tamayo, Cassandra M. J. Wannan, Alana Wickham, Walid Yassin, Juan Helen Zhou, Jean Addington, Luis Alameda, Celso Arango, Nicholas J. K. Breitborde, Matthew R. Broome, Kristin S. Cadenhead, Monica E. Calkins, Eric Yu Hai Chen, Jimmy Choi, Philippe Conus, Cheryl Mary Corcoran, Barbara A. Cornblatt, Covadonga Martínez Díaz-Caneja, Lauren M. Ellman, Paolo Fusar‐Poli, Pablo A. Gaspar, Carla Gerber, Louise Birkedal Glenthøj, Leslie E. Horton, Christy Lai Ming Hui, Joseph P. Kambeitz, Lana Kambeitz‐Ilankovic, Matcheri S. Keshavan, Sung‐Wan Kim, Nikolaos Koutsouleris, Jun Soo Kwon, Kerstin Langbein, Daniel Mamah, Daniel H. Mathalon, Vijay Anand Mittal, Merete Nordentoft, Godfrey D. Pearlson, Jesús Pérez, Diana O. Perkins, Albert R. Powers, Jack C Rogers, Fred W. Sabb, Jason Eric Schiffman, Jai L. Shah, Steven M. Silverstein, Stefan Smesny, William S. Stone, Gregory P. Strauss, Judy L. Thompson, Rachel Upthegrove, Swapna Kamal Verma, Jijun Wang, Daniel H. Wolf, René S. Kahn, John Michael Kane, Patrick D. McGorry, Barnaby Nelson, Scott W. Woods, Martha E. Shenton, Stephen James Wood, Carrie E. Bearden, Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ), Ofer Pasternak · 发表于：Schizophrenia · 年份：2025 · DOI：10.1038/s41537-025-00581-6 · 被引用次数：10 · 研究领域：Functional Brain Connectivity Studies、Advanced Neuroimaging Techniques and Applications、Advanced MRI Techniques and Applications

Neuroimaging with MRI has been a frequent component of studies of individuals at clinical high risk (CHR) for developing psychosis, with goals of understanding potential brain regions and systems impacted in the CHR state and identifying prognostic or predictive biomarkers that can enhance our ability to forecast clinical outcomes. To date, most studies involving MRI in CHR are likely not sufficiently powered to generate robust and generalizable neuroimaging results. Here, we describe the prospective, advanced, and modern neuroimaging protocol that was implemented in a complex multi-site, multi-vendor environment, as part of the large-scale Accelerating Medicines Partnership® Schizophrenia Program (AMP® SCZ), including the rationale for various choices. This protocol includes T1- and T2-weighted structural scans, resting-state fMRI, and diffusion-weighted imaging collected at two time points, approximately 2 months apart. We also present preliminary variance component analyses of several measures, such as signal- and contrast-to-noise ratio (SNR/CNR) and spatial smoothness, to provide quantitative data on the relative percentages of participant, site, and platform (i.e., scanner model) variance. Site-related variance is generally small (typically <10%). For the SNR/CNR measures from the structural and fMRI scans, participant variance is the largest component (as desired; 40-76%). However, for SNR/CNR in the diffusion scans, there is substantial platform-related variance (>55%...